Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating OverviewBusiness Wire • 05/07/25
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care ConferenceBusiness Wire • 05/05/25
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to DeclineZacks Investment Research • 04/30/25
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025Business Wire • 04/23/25
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in MedBusiness Wire • 03/05/25
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)Zacks Investment Research • 03/05/25
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)Zacks Investment Research • 03/04/25
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 StudyBusiness Wire • 03/03/25
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care ConferenceBusiness Wire • 02/27/25
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue GrowthZacks Investment Research • 02/27/25
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewBusiness Wire • 02/26/25
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?Zacks Investment Research • 02/13/25
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025Business Wire • 02/12/25
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)Zacks Investment Research • 01/16/25
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline GoalsZacks Investment Research • 01/15/25
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/14/25
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 01/14/25
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025Business Wire • 12/19/24
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionBusiness Wire • 12/11/24